第二次局灶性高强度聚焦超声(HIFU)治疗后的功能结局评估:HEAT登记研究
本研究基于多中心HEAT登记数据,比较821例局限性非转移性前列腺癌患者接受一次与二次局灶性HIFU后的功能结局变化。二次HIFU后IPSS轻度升高、勃起功能轻度下降,新发尿垫使用率低,对排尿功能和勃起功能影响轻微,可用于患者咨询。
要点
- 二次局灶HIFU后1-2年IPSS平均变化+1.4(P=0.03),2-3年+1.2(P=0.003)。
- 二次HIFU后1-2年新发勃起功能障碍17.8%,2-3年6.2%,EF评分变化无统计学意义。
- 二次HIFU后新发尿垫使用率1-2年1.8%、2-3年2.6%,对控尿影响轻微。
核心结论
- 第二次局灶性HIFU对排尿功能和勃起功能仅造成轻微不利影响。
- 该数据可用于非转移性前列腺癌患者考虑HIFU治疗前的咨询。
研究设计与样本
- 多中心研究(2005-2016年),821例局限性非转移性前列腺癌男性接受局灶性HIFU。
- 654例接受一次局灶HIFU,167例接受第二次局灶HIFU。
- 前瞻性收集IPSS、尿垫使用和勃起功能评分至3年,要求至少完成一次随访问卷。
- 一次HIFU组355例(54.3%)和二次HIFU组65例(38.9%)返回随访问卷。
- 一次HIFU组平均年龄66.4岁、PSA 7.9 ng/mL;二次HIFU组平均年龄65.6岁、PSA 8.4 ng/mL。
主要发现
- 一次局灶HIFU后1-2年IPSS平均变化-0.03(P=0.02),IIEF勃起功能评分平均变化-0.4(P=0.02),此后无进一步下降。
- 一次HIFU后1-2年勃起功能障碍绝对率从9.9%升至20.8%(P=0.08),无漏尿控尿率从77.9%降至72.8%(P=0.06),无尿垫控尿率从98.6%降至94.8%(P=0.07)。
- 第二次HIFU前IPSS较第一次HIFU前基线低1.3(P=0.02)。
- 第二次HIFU后1-2年IPSS平均变化+1.4(P=0.03),2-3年+1.2(P=0.003)。
- 第二次HIFU后EF评分平均变化1-2年-0.2(P=0.60)、2-3年-0.5(P=0.10),新发勃起功能障碍分别为17.8%和6.2%。
临床怎么用
- 向考虑局灶性HIFU的非转移性前列腺癌患者咨询时,可告知二次HIFU对排尿和勃起功能影响轻微。
- 二次HIFU后应关注IPSS轻度升高和勃起功能变化,但新发尿失禁风险较低。
局限性
- 一次HIFU组和二次HIFU组随访问卷返回率分别为54.3%和38.9%,存在随访选择偏倚可能。
- 功能结局基于患者报告问卷,部分比较的P值未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess change in functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) treatment compared with outcomes after one focal HIFU treatment. PATIENTS AND METHODS: In this multicentre study (2005-2016), 821 men underwent focal HIFU for localized non-metastatic prostate cancer. The patient-reported outcome measures of International Prostate Symptom Score (IPSS), pad usage and erectile function (EF) score were prospectively collected for up to 3 years. To be included in the study, completion of at least one follow-up questionnaire was required. The primary outcome was comparison of change in functional outcomes between baseline and follow-up after one focal HIFU procedure vs after a second focal HIFU procedure, using IPSS, Expanded Prostate Cancer Index Composite (EPIC) and International Index of Erectile Function (IIEF) questionnaires. RESULTS: Of 821 men, 654 underwent one focal HIFU procedure and 167 underwent a second focal HIFU procedure. A total of 355 (54.3%) men undergoing one focal HIFU procedure and 65 (38.9%) with a second focal HIFU procedure returned follow-up questionnaires, respectively. The mean age and prostate-specific antigen level were 66.4 and 65.6 years, and 7.9 and 8.4 ng/mL, respectively. After one focal HIFU treatment, the mean change in IPSS was -0.03 (P = 0.02) and in IIEF (EF score) it was -0.4 (P = 0.02) at 1-2 years, with no subsequent decline. Absolute rates of erectile dysfunction increased from 9.9% to 20.8% (P = 0.08), leak-free continence decreased from 77.9% to 72.8% (P = 0.06) and pad-free continence from 98.6% to 94.8% (P = 0.07) at 1-2 years, respectively. IPSS prior to second focal HIFU treatment compared to baseline IPSS prior to first focal HIFU treatment was lower by -1.3 (P = 0.02), but mean IPSS change was +1.4 at 1-2 years (P = 0.03) and +1.2 at 2-3 years (P = 0.003) after the second focal HIFU treatment. The mean change in EF score after the second focal HIFU treatment was -0.2 at 1-2 years (P = 0.60) and -0.5 at 2-3 years (P = 0.10), with 17.8% and 6.2% of men with new erectile dysfunction. The rate of new pad use was 1.8% at 1-2 years and 2.6% at 2-3 years. CONCLUSION: A second focal HIFU procedure causes minor detrimental effects on urinary function and EF. These data can be used to counsel patients with non-metastatic prostate cancer prior to considering HIFU therapy.
引用
- Lovegrove CE, Peters M, Guillaumier S, et al. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU Int. 2020. PMID: 31971335. doi:10.1111/bju.15004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。